Savara Inc., a clinical-stage biopharmaceutical company, is developing MOLBREEVI, an inhaled biologic for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The company has received multiple expedited regulatory designations and recently had its resubmitted Biologics License Application (BLA) accepted with Priority Review by the FDA. Despite this progress, Savara continues to incur significant operating losses and negative cash flow due to ongoing clinical development and commercialization preparation. The company’s capital structure includes substantial equity raises and debt financing, supporting its outsourced operational model. Upcoming FDA decisions and capital management will be critical for Savara's path forward.